A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
Li-Xin GuoLi ChenBaocheng ChangLiyong YangYu LiuBo FengPublished in: Diabetes, obesity & metabolism (2018)
BIAsp 30 plus metformin was non-inferior to BIAsp 30 in safely reducing HbA1c in this study.